BE2013C063I2 - - Google Patents
Download PDFInfo
- Publication number
- BE2013C063I2 BE2013C063I2 BE2013C063C BE2013C063C BE2013C063I2 BE 2013C063 I2 BE2013C063 I2 BE 2013C063I2 BE 2013C063 C BE2013C063 C BE 2013C063C BE 2013C063 C BE2013C063 C BE 2013C063C BE 2013C063 I2 BE2013C063 I2 BE 2013C063I2
- Authority
- BE
- Belgium
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002336843 | 2002-11-20 | ||
| JP2003065807 | 2003-03-11 | ||
| JP2003139616 | 2003-05-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE2013C063I2 true BE2013C063I2 (me) | 2023-03-07 |
Family
ID=32329647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE2013C063C BE2013C063I2 (me) | 2002-11-20 | 2013-11-14 |
Country Status (32)
| Country | Link |
|---|---|
| US (6) | US7176220B2 (me) |
| EP (5) | EP1564210B9 (me) |
| KR (1) | KR100665919B1 (me) |
| AR (2) | AR042095A1 (me) |
| AT (1) | ATE443048T1 (me) |
| AU (1) | AU2003302029B8 (me) |
| BE (1) | BE2013C063I2 (me) |
| BR (1) | BRPI0306214B1 (me) |
| CA (1) | CA2470365C (me) |
| CY (2) | CY1110690T1 (me) |
| CZ (1) | CZ2004764A3 (me) |
| DE (1) | DE60329318D1 (me) |
| DK (1) | DK1564210T5 (me) |
| ES (1) | ES2329240T3 (me) |
| FR (1) | FR13C0061I2 (me) |
| HK (1) | HK1080852A1 (me) |
| HU (1) | HUS1300066I1 (me) |
| IL (2) | IL162548A0 (me) |
| LT (1) | LTPA2013018I1 (me) |
| LU (1) | LU92307I2 (me) |
| MX (1) | MXPA04006553A (me) |
| MY (1) | MY136173A (me) |
| NO (3) | NO327098B1 (me) |
| NZ (1) | NZ533641A (me) |
| PE (1) | PE20040840A1 (me) |
| PT (1) | PT1564210E (me) |
| SI (1) | SI1564210T1 (me) |
| SK (1) | SK2662004A3 (me) |
| TR (1) | TR200401663T1 (me) |
| TW (1) | TWI248928B (me) |
| WO (1) | WO2004046115A1 (me) |
| ZA (1) | ZA200404537B (me) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3927175B2 (ja) | 2001-10-26 | 2007-06-06 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | Ｎ−置換ヒドロキシピリミジノンカルボキサミド系ｈｉｖインテグラーゼ阻害薬 |
| MY136173A (en) * | 2002-11-20 | 2008-08-29 | Japan Tobacco Inc | 4-oxoquinoline compound and use thereof as hiv integrase inhibitor |
| DE602005023717D1 (de) | 2004-03-10 | 2010-11-04 | Usa | Chinolin-4-one als inhibitoren der retroviralen integrase zur behandlung von hiv, aids und aids-related complex (arc) |
| MY134672A (en) * | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
| US7531554B2 (en) | 2004-05-20 | 2009-05-12 | Japan Tobacco Inc. | 4-oxoquinoline compound and use thereof as HIV integrase inhibitor |
| US8633219B2 (en) * | 2004-05-21 | 2014-01-21 | Japan Tobacco Inc. | Combination therapy |
| WO2006033422A1 (ja) * | 2004-09-21 | 2006-03-30 | Japan Tobacco Inc. | キノリジノン化合物、およびそのｈｉｖインテグラーゼ阻害剤としての利用 |
| US7745459B2 (en) | 2004-09-21 | 2010-06-29 | Japan Tobacco Inc. | Quinolizinone compound and use thereof as HIV integrase inhibitor |
| UA87884C2 (uk) * | 2004-12-03 | 2009-08-25 | Мерк Энд Ко., Инк. | Безводна кристалічна калієва сіль інгібітора віл-інтегрази |
| US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
| US20070032522A1 (en) * | 2005-07-01 | 2007-02-08 | Kumar Dange V | Antiviral agents |
| WO2007063869A1 (ja) * | 2005-11-30 | 2007-06-07 | Japan Tobacco Inc. | 高純度キノロン化合物の製造方法 |
| US20090233964A1 (en) * | 2005-12-30 | 2009-09-17 | Gilead Sciences, Inc. | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
| AU2013203476C1 (en) * | 2005-12-30 | 2016-11-17 | Gilead Sciences, Inc. | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
| SG170796A1 (en) * | 2005-12-30 | 2011-05-30 | Gilead Sciences Inc Us | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
| EP1978960A4 (en) * | 2006-02-01 | 2009-12-02 | Japan Tobacco Inc | USE OF 6- (3-CHLORO-2-FLUORBENZYL) -1 - [(2S) -1-HYDROXY-3-METHYLBUTAN-2-YL [-7-METHOXY-4-OXO-1,4-DIHYDROCHINOLINE-3- CARBOXYLIC ACID OR SALT THEREOF FOR THE TREATMENT OF RETROVIRUS INFECTION |
| WO2007092802A1 (en) * | 2006-02-09 | 2007-08-16 | Boehringer Ingelheim International Gmbh | Method for treating hiv infection through co-administration of tipranavir and gs 9137 |
| AU2007223260C1 (en) * | 2006-03-06 | 2011-02-03 | Japan Tobacco Inc. | Method for producing 4-oxoquinoline compound |
| WO2007102499A1 (ja) * | 2006-03-06 | 2007-09-13 | Japan Tobacco Inc. | ４－オキソキノリン化合物の製造方法 |
| PE20080697A1 (es) | 2006-05-03 | 2008-08-05 | Boehringer Ingelheim Int | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
| TW200811153A (en) * | 2006-06-23 | 2008-03-01 | Japan Tobacco Inc | 6-(heterocyclyl-substituted benzyl)-4-oxoquinoline compound and use thereof as HIV integrase inhibitor |
| AP2985A (en) | 2006-07-07 | 2014-09-30 | Gilead Sciences Inc | Modulators of pharmacokinetic properties of therapeutics |
| JP2009543865A (ja) * | 2006-07-19 | 2009-12-10 | ユニバーシティ オブ ジョージア リサーチ ファウンデーション， インコーポレーテッド | ピリジノンジケト酸：併用療法におけるｈｉｖ複製の阻害剤 |
| SG10201501782UA (en) * | 2006-09-12 | 2015-05-28 | Gilead Sciences Inc | Process and intermediates for preparing integrase inhibitors |
| CA2664396A1 (en) | 2006-09-29 | 2008-04-10 | Idenix Pharmaceuticals, Inc. | Enantiomerically pure phosphoindoles as hiv inhibitors |
| AU2007336703B9 (en) | 2006-12-22 | 2014-03-27 | Avexa Limited | Bicyclic pyrimidinones and uses thereof |
| ES2602784T3 (es) | 2007-02-23 | 2017-02-22 | Gilead Sciences, Inc. | Moduladores de las propiedades farmacocinéticas de los agentes terapéuticos |
| CN101743004A (zh) * | 2007-06-29 | 2010-06-16 | 吉里德科学公司 | 治疗用组合物及其用途 |
| BRPI0813000A2 (pt) * | 2007-06-29 | 2014-12-23 | Gilead Sciences Inc | Composições terapêuticas e uso das mesmas |
| PE20090938A1 (es) | 2007-08-16 | 2009-08-08 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo |
| AR068403A1 (es) * | 2007-09-11 | 2009-11-18 | Gilead Sciences Inc | Proceso e intermediarios para la preparacion de inhibidores de integrasa |
| US7994194B2 (en) * | 2007-09-12 | 2011-08-09 | Concert Pharmaceuticals, Inc. | 4-oxoquinoline derivatives |
| CA2705318C (en) * | 2007-11-15 | 2013-12-31 | Boehringer Ingelheim International Gmbh | Inhibitors of human immunodeficiency virus replication |
| JP5285709B2 (ja) | 2007-11-16 | 2013-09-11 | ギリアード サイエンシス インコーポレーテッド | ヒト免疫不全ウイルスの複製阻害薬 |
| JP2011517313A (ja) | 2007-12-11 | 2011-06-02 | ビアメト ファーマシューティカルズ，インク． | 金属結合部分を標的化部分と組み合わせて使用する金属酵素阻害剤 |
| EP2231665A4 (en) * | 2008-01-07 | 2012-04-25 | Ardea Biosciences Inc | NEW COMPOSITIONS AND METHODS OF USE |
| CN104940937A (zh) * | 2008-05-02 | 2015-09-30 | 吉里德科学公司 | 固体载体颗粒在改善药物制剂加工性中的应用 |
| WO2010073078A2 (en) * | 2008-12-22 | 2010-07-01 | Orchid Research Laboratories Ltd. | Heterocyclic compounds as hdac inhibitors |
| US20100285122A1 (en) * | 2009-02-06 | 2010-11-11 | Gilead Sciences, Inc. | Tablets for combination therapy |
| PT2395983T (pt) | 2009-02-13 | 2020-07-03 | Boehringer Ingelheim Int | Composição farmacêutica compreendendo um inibidor de sglt2, um inibidor de dp-iv e opcionalmente um agente antidiabético adicional e suas utilizações |
| WO2010137032A2 (en) | 2009-05-14 | 2010-12-02 | Matrix Laboratories Ltd. | Novel polymorphic forms of elvitegravir and its pharmaceutically acceptable salts |
| WO2011004389A2 (en) | 2009-06-18 | 2011-01-13 | Matrix Laboratories Ltd | An improved process for the preparation of elvitegravir |
| EP2470014A4 (en) * | 2009-08-26 | 2013-01-16 | Merck Sharp & Dohme | HIV integrase inhibitors |
| BR112012007085B8 (pt) | 2009-09-30 | 2021-05-25 | Boehringer Ingelheim Int | processos para a preparação de derivados de benzil-benzeno substituídos com glicopiranosila |
| AU2010303123B2 (en) | 2009-09-30 | 2014-02-27 | Boehringer Ingelheim International Gmbh | Method for the preparation of a crystalline form of 1-chloro-4- (Beta-D-glucopyranos-1-yl)-2-(4-((S)-tetrahydrofuran-3-yloxy)benzyl)benzene |
| US10610489B2 (en) | 2009-10-02 | 2020-04-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
| US8497270B2 (en) | 2009-10-13 | 2013-07-30 | Elanco Animal Health Ireland Limited | Macrocyclic integrase inhibitors |
| US8703801B2 (en) | 2009-12-07 | 2014-04-22 | University Of Georgia Research Foundation, Inc. | Pyridinone hydroxycyclopentyl carboxamides: HIV integrase inhibitors with therapeutic applications |
| EP2552923B1 (en) | 2010-04-02 | 2014-03-26 | Janssen R&D Ireland | Macrocyclic integrase inhibitors |
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| MX2012015293A (es) | 2010-07-02 | 2013-05-30 | Gilead Sciences Inc | Derivados de acido 2-quinolinil-acetico como compuestos antivirales. |
| EP2588450B1 (en) | 2010-07-02 | 2017-05-24 | Gilead Sciences, Inc. | Napht-2-ylacetic acid derivatives to treat aids |
| UY33937A (es) | 2011-03-07 | 2012-09-28 | Boehringer Ingelheim Int | Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina |
| EP3181555B1 (en) | 2011-04-21 | 2018-11-28 | Gilead Sciences, Inc. | Benzothiazole compounds and their pharmaceutical use |
| WO2013103724A1 (en) | 2012-01-04 | 2013-07-11 | Gilead Sciences, Inc. | 2- (tert - butoxy) -2- (7 -methylquinolin- 6 - yl) acetic acid derivatives for treating aids |
| US9284323B2 (en) | 2012-01-04 | 2016-03-15 | Gilead Sciences, Inc. | Naphthalene acetic acid derivatives against HIV infection |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| US9192617B2 (en) | 2012-03-20 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US9096586B2 (en) | 2012-04-20 | 2015-08-04 | Gilead Sciences, Inc. | Therapeutic compounds |
| MX337094B (es) * | 2012-08-03 | 2016-02-10 | Gilead Sciences Inc | Proceso e intermediarios para preparar inhibidores de integrasa. |
| CZ304983B6 (cs) | 2012-10-12 | 2015-03-11 | Zentiva, K.S. | Způsob výroby a nové intermediáty syntézy elvitegraviru |
| CZ304984B6 (cs) | 2012-10-12 | 2015-03-11 | Zentiva, K.S. | Zlepšený způsob výroby a nové intermediáty syntézy elvitegraviru |
| DK3608325T3 (da) | 2012-12-21 | 2022-08-22 | Gilead Sciences Inc | Polycykliske-carbamoylpyridonforbindelser og deres farmaceutiske anvendelse |
| JP2016509473A (ja) | 2012-12-26 | 2016-03-31 | ネステク ソシエテ アノニム | 低密度の被覆された動物用敷材組成物 |
| US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| PT2981271T (pt) | 2013-04-05 | 2019-02-19 | Boehringer Ingelheim Int | Utilizações terapêuticas de empagliflozina |
| US20140303097A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| WO2014170383A1 (en) | 2013-04-18 | 2014-10-23 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CZ307255B6 (cs) | 2013-07-11 | 2018-05-02 | Zentiva, K.S. | Nový způsob přípravy elvitegraviru |
| EP3019503B1 (en) | 2013-07-12 | 2017-09-06 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections |
| NO2865735T3 (me) | 2013-07-12 | 2018-07-21 | ||
| TWI744723B (zh) | 2014-06-20 | 2021-11-01 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
| NO2717902T3 (me) | 2014-06-20 | 2018-06-23 | ||
| TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
| WO2016081464A1 (en) | 2014-11-17 | 2016-05-26 | Nirogyone Therapeutics, Inc. | Monocarboxylate transport modulators and uses thereof |
| TWI695003B (zh) | 2014-12-23 | 2020-06-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
| SI3466490T1 (sl) | 2015-04-02 | 2020-12-31 | Gilead Sciences, Inc. | Policiklične spojine karbamoilpiridona in njihova farmacevtska uporaba |
| WO2016193997A2 (en) * | 2015-06-03 | 2016-12-08 | Msn Laboratories Private Limited | Process for the preparation of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid and pharmaceutically acceptable salts thereof |
| EP3364752B1 (en) | 2015-10-23 | 2022-07-06 | Société des Produits Nestlé S.A. | Low density pet litters and methods of making and using such pet litters |
| RU2654062C2 (ru) * | 2016-07-14 | 2018-05-16 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Производные хиназолин-4(3н)-она, ингибирующие натрий-водородный обмен |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3472859A (en) * | 1966-11-01 | 1969-10-14 | Sterling Drug Inc | 1-alkyl-1,4-dihydro-4-oxo-3 quinoline-carboxylic acids and esters |
| JPS4826772A (me) | 1971-08-11 | 1973-04-09 | ||
| DE3501247A1 (de) * | 1985-01-16 | 1986-07-17 | Bayer Ag, 5090 Leverkusen | Aminoacrylsaeure-derivate |
| US5563138A (en) * | 1987-04-16 | 1996-10-08 | Otsuka Pharmaceutical Company, Limited | Benzoheterocyclic compounds |
| EP0319906A3 (en) * | 1987-12-11 | 1990-05-02 | Dainippon Pharmaceutical Co., Ltd. | Novel quinoline derivatives, processes for preparation thereof and antibacterial agent containing them |
| US4920120A (en) * | 1988-01-25 | 1990-04-24 | Warner-Lambert Company | Antibacterial agents |
| DE3934082A1 (de) * | 1989-10-12 | 1991-04-18 | Bayer Ag | Chinoloncarbonsaeurederivate, verfahren zu ihrer herstellung sowie ihre verwendung als antivirale mittel |
| DE4015299A1 (de) * | 1990-05-12 | 1991-11-14 | Bayer Ag | Verfahren zur herstellung von 3-amino-2-(het)-aroyl-acrylsaeurederivaten |
| IL100555A (en) | 1991-02-07 | 2000-08-31 | Hoechst Marion Roussel Inc | N-substituted quinoline derivatives their preparation their use for the preparation of medicaments and the pharmaceutical compositions containing them |
| JP2993316B2 (ja) | 1992-05-27 | 1999-12-20 | 宇部興産株式会社 | アリール基又は複素芳香環基置換アミノキノロン誘導体及びエイズ治療剤 |
| NO304832B1 (no) | 1992-05-27 | 1999-02-22 | Ube Industries | Aminokinolonderivater samt middel mot HIV |
| JPH06199635A (ja) | 1992-12-28 | 1994-07-19 | Kanebo Ltd | 化粧料 |
| JPH06199835A (ja) | 1993-01-08 | 1994-07-19 | Hokuriku Seiyaku Co Ltd | ８−ジフルオロメトキシキノリン−３−カルボン酸誘導体 |
| JPH06271568A (ja) | 1993-03-22 | 1994-09-27 | Hokuriku Seiyaku Co Ltd | ７−フェニルピペラジニルキノリン−３−カルボン酸誘導体 |
| WO1995029891A1 (fr) | 1994-04-28 | 1995-11-09 | Yamanouchi Pharmaceutical Co., Ltd. | Derive de n-(3-pyrrolidinyl)benzamide |
| HUT76643A (en) | 1994-07-18 | 1997-10-28 | Sankyo Co | Trifluoromethylquinolinecarboxylic acid derivative, pharmaceutical compositions containing them and their use |
| JP2930539B2 (ja) | 1994-07-18 | 1999-08-03 | 三共株式会社 | トリフルオロメチルキノリンカルボン酸誘導体 |
| JPH08183776A (ja) | 1994-12-28 | 1996-07-16 | Hideaki Yamaguchi | 金属の表面保護剤ならびにそれを用いた製造方法 |
| US6303611B1 (en) * | 1996-03-08 | 2001-10-16 | Adolor Corporation | Kappa agonist compounds and pharmaceutical formulations thereof |
| DE69709857T2 (de) | 1996-04-12 | 2002-08-29 | Us Gov Health & Human Serv | Acridonderivate als antineoplastische-und antiretrovirale mittel |
| US6287550B1 (en) * | 1996-12-17 | 2001-09-11 | The Procter & Gamble Company | Animal care system and litter with reduced malodor impression |
| US5989451A (en) | 1997-02-07 | 1999-11-23 | Queen's University At Kingston | Compounds and methods for doping liquid crystal hosts |
| FR2761687B1 (fr) * | 1997-04-08 | 2000-09-15 | Centre Nat Rech Scient | Derives de quinoleines, possedant notamment des proprietes antivirales, leurs preparations et leurs applications biologiques |
| JP3776203B2 (ja) | 1997-05-13 | 2006-05-17 | 第一製薬株式会社 | Ｉｃａｍ−１産生阻害剤 |
| KR20010013377A (ko) * | 1997-06-04 | 2001-02-26 | 데이비드 엠 모이어 | 마일드한 잔류성 항균 조성물 |
| TW527355B (en) * | 1997-07-02 | 2003-04-11 | Bristol Myers Squibb Co | Inhibitors of farnesyl protein transferase |
| JPH1184556A (ja) | 1997-09-08 | 1999-03-26 | Konica Corp | ハロゲン化銀乳剤、該乳剤を用いる感光材料の処理方法及び撮影方法 |
| GB9721964D0 (en) * | 1997-10-16 | 1997-12-17 | Pfizer Ltd | Isoquinolines |
| GB9807903D0 (en) | 1998-04-14 | 1998-06-10 | Smithkline Beecham Plc | Novel compounds |
| US6399629B1 (en) * | 1998-06-01 | 2002-06-04 | Microcide Pharmaceuticals, Inc. | Efflux pump inhibitors |
| US6248739B1 (en) * | 1999-01-08 | 2001-06-19 | Pharmacia & Upjohn Company | Quinolinecarboxamides as antiviral agents |
| US6248736B1 (en) | 1999-01-08 | 2001-06-19 | Pharmacia & Upjohn Company | 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents |
| FR2795726A1 (fr) | 1999-06-30 | 2001-01-05 | Aventis Cropscience Sa | Nouveaux pyrazoles fongicides |
| DE19950898A1 (de) * | 1999-10-22 | 2001-04-26 | Aventis Pharma Gmbh | Heterocyclisch substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| PE20011349A1 (es) | 2000-06-16 | 2002-01-19 | Upjohn Co | 1-aril-4-oxo-1,4-dihidro-3-quinolincarboxamidas como agentes antivirales |
| US6730682B2 (en) * | 2000-07-12 | 2004-05-04 | Pharmacia & Upjohn Company | Heterocycle carboxamides as antiviral agents |
| US6559145B2 (en) | 2000-07-12 | 2003-05-06 | Pharmacia & Upjohn Company | Heterocycle carboxamides as antiviral agents |
| US20050010048A1 (en) | 2000-10-12 | 2005-01-13 | Linghang Zhuang | Aza-and polyaza-naphthalenly ketones useful as hiv integrase inhibitors |
| ATE345129T1 (de) | 2000-10-12 | 2006-12-15 | Merck & Co Inc | Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer |
| ATE300522T1 (de) * | 2000-12-14 | 2005-08-15 | Procter & Gamble | Cyclisierungsverfahrensschritt bei der herstellung von chinolonen und naphthyridinen |
| AU2002305926A1 (en) * | 2001-02-05 | 2002-10-08 | Exegenics Inc. | Cysteine protease inhibitors |
| DE60229364D1 (de) | 2001-03-01 | 2008-11-27 | Shionogi & Co | Stickstoffhaltige heteroarylverbindungen mit hiv-integrase inhibierender wirkung |
| JP4518302B2 (ja) | 2001-03-19 | 2010-08-04 | 日本化薬株式会社 | 水溶性ジスアゾ化合物、水性ブラックインク組成物および着色体 |
| JP2002293745A (ja) | 2001-03-29 | 2002-10-09 | St Marianna Univ School Of Medicine | 慢性関節リウマチ治療剤 |
| JP3980842B2 (ja) | 2001-05-11 | 2007-09-26 | バブコック日立株式会社 | アンモニア含有排水の浄化装置および浄化方法 |
| JP2003065807A (ja) | 2001-08-29 | 2003-03-05 | Mitsubishi Electric Corp | プロセスデータのトレンド表示方法および装置 |
| JP3913037B2 (ja) | 2001-10-30 | 2007-05-09 | 三菱電機株式会社 | 赤外線検出器 |
| TW200300349A (en) | 2001-11-19 | 2003-06-01 | Sankyo Co | A 4-oxoqinoline derivative |
| MY136173A (en) * | 2002-11-20 | 2008-08-29 | Japan Tobacco Inc | 4-oxoquinoline compound and use thereof as hiv integrase inhibitor |
| JP2004253231A (ja) | 2003-02-20 | 2004-09-09 | Pioneer Electronic Corp | プラズマディスプレイパネル |
| MY134672A (en) * | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
| US7531554B2 (en) * | 2004-05-20 | 2009-05-12 | Japan Tobacco Inc. | 4-oxoquinoline compound and use thereof as HIV integrase inhibitor |
| US8633219B2 (en) * | 2004-05-21 | 2014-01-21 | Japan Tobacco Inc. | Combination therapy |
| AU2007223260C1 (en) | 2006-03-06 | 2011-02-03 | Japan Tobacco Inc. | Method for producing 4-oxoquinoline compound |
| WO2007102499A1 (ja) | 2006-03-06 | 2007-09-13 | Japan Tobacco Inc. | ４－オキソキノリン化合物の製造方法 |
| TW200811153A (en) * | 2006-06-23 | 2008-03-01 | Japan Tobacco Inc | 6-(heterocyclyl-substituted benzyl)-4-oxoquinoline compound and use thereof as HIV integrase inhibitor |
| SG10201501782UA (en) * | 2006-09-12 | 2015-05-28 | Gilead Sciences Inc | Process and intermediates for preparing integrase inhibitors |
| AR068403A1 (es) | 2007-09-11 | 2009-11-18 | Gilead Sciences Inc | Proceso e intermediarios para la preparacion de inhibidores de integrasa |
| US7994194B2 (en) * | 2007-09-12 | 2011-08-09 | Concert Pharmaceuticals, Inc. | 4-oxoquinoline derivatives |
| EP2231665A4 (en) | 2008-01-07 | 2012-04-25 | Ardea Biosciences Inc | NEW COMPOSITIONS AND METHODS OF USE |
| SI23420A (sl) | 2010-07-22 | 2012-01-31 | Institut "Jožef Stefan" | Kostni vsadki z večslojno prevleko in postopek njihove priprave |
| US11347056B2 (en) | 2018-08-22 | 2022-05-31 | Microsoft Technology Licensing, Llc | Foveated color correction to improve color uniformity of head-mounted displays |
| EP3842777B1 (en) | 2018-08-23 | 2024-05-15 | LG Innotek Co., Ltd. | Sensing device |
| WO2020040561A1 (ko) | 2018-08-24 | 2020-02-27 | 한온시스템 주식회사 | 차량용 공조장치 |
-
2003
- 2003-11-20 MY MYPI20034478A patent/MY136173A/en unknown
- 2003-11-20 IL IL16254803A patent/IL162548A0/xx unknown
- 2003-11-20 KR KR1020047010082A patent/KR100665919B1/ko active Protection Beyond IP Right Term
- 2003-11-20 WO PCT/JP2003/014773 patent/WO2004046115A1/ja active IP Right Grant
- 2003-11-20 EP EP03811532A patent/EP1564210B9/en not_active Expired - Lifetime
- 2003-11-20 EP EP18166352.7A patent/EP3406596A1/en not_active Withdrawn
- 2003-11-20 CA CA2470365A patent/CA2470365C/en not_active Expired - Lifetime
- 2003-11-20 EP EP22158433.7A patent/EP4059923A1/en active Pending
- 2003-11-20 PT PT03811532T patent/PT1564210E/pt unknown
- 2003-11-20 SK SK266-2004A patent/SK2662004A3/sk not_active Application Discontinuation
- 2003-11-20 TR TR2004/01663T patent/TR200401663T1/xx unknown
- 2003-11-20 CZ CZ2004764A patent/CZ2004764A3/cs unknown
- 2003-11-20 US US10/492,833 patent/US7176220B2/en active Active
- 2003-11-20 PE PE2003001176A patent/PE20040840A1/es active IP Right Grant
- 2003-11-20 EP EP09169859A patent/EP2161258A3/en not_active Withdrawn
- 2003-11-20 NZ NZ533641A patent/NZ533641A/en not_active IP Right Cessation
- 2003-11-20 AT AT03811532T patent/ATE443048T1/de active
- 2003-11-20 DK DK03811532.5T patent/DK1564210T5/da active
- 2003-11-20 BR BRPI0306214-7A patent/BRPI0306214B1/pt active IP Right Grant
- 2003-11-20 EP EP10011216A patent/EP2272516A3/en not_active Withdrawn
- 2003-11-20 DE DE60329318T patent/DE60329318D1/de not_active Expired - Lifetime
- 2003-11-20 AR ARP030104286A patent/AR042095A1/es active IP Right Grant
- 2003-11-20 AU AU2003302029A patent/AU2003302029B8/en active Active
- 2003-11-20 TW TW092132527A patent/TWI248928B/zh not_active IP Right Cessation
- 2003-11-20 ES ES03811532T patent/ES2329240T3/es not_active Expired - Lifetime
- 2003-11-20 SI SI200331707T patent/SI1564210T1/sl unknown
-
2004
- 2004-06-08 ZA ZA2004/04537A patent/ZA200404537B/en unknown
- 2004-06-16 IL IL162548A patent/IL162548A/en active Protection Beyond IP Right Term
- 2004-07-02 MX MXPA04006553A patent/MXPA04006553A/es active IP Right Grant
- 2004-07-14 NO NO20043004A patent/NO327098B1/no not_active IP Right Cessation
-
2006
- 2006-01-18 HK HK06100829.1A patent/HK1080852A1/xx not_active IP Right Cessation
- 2006-06-05 US US11/446,128 patent/US8232401B2/en active Active
-
2009
- 2009-12-11 CY CY20091101301T patent/CY1110690T1/el unknown
-
2012
- 2012-06-20 US US13/528,688 patent/US20130172344A1/en not_active Abandoned
- 2012-07-03 AR ARP120102410A patent/AR087046A2/es unknown
-
2013
- 2013-07-12 LT LTPA2013018C patent/LTPA2013018I1/lt unknown
- 2013-11-07 NO NO2013015C patent/NO2013015I2/no unknown
- 2013-11-07 HU HUS1300066C patent/HUS1300066I1/hu unknown
- 2013-11-11 LU LU92307C patent/LU92307I2/fr unknown
- 2013-11-12 FR FR13C0061C patent/FR13C0061I2/fr active Active
- 2013-11-14 BE BE2013C063C patent/BE2013C063I2/fr unknown
- 2013-11-18 CY CY2013043C patent/CY2013043I1/el unknown
-
2014
- 2014-06-10 US US14/301,083 patent/US20150174117A1/en not_active Abandoned
-
2019
- 2019-05-10 US US16/409,728 patent/US20200101061A1/en not_active Abandoned
-
2022
- 2022-05-13 US US17/663,391 patent/US20230190730A1/en not_active Abandoned
- 2022-07-22 NO NO2022032C patent/NO2022032I1/no unknown